Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Kgatle, Mankgopo![]() |
|
dc.contributor.author | Das, Rajesh![]() |
|
dc.contributor.author | Lawal, Ismaheel Opeyemi![]() |
|
dc.contributor.author | Boshomane, Tebatso M.G.![]() |
|
dc.contributor.author | Mokoala, Kgomotso M.G.![]() |
|
dc.contributor.author | Gaspar, Cattleya![]() |
|
dc.contributor.author | Mbokazi, Lydia![]() |
|
dc.contributor.author | Nkambule, Nonhlanhla![]() |
|
dc.contributor.author | Gow, Veronique![]() |
|
dc.contributor.author | Ndlovu, Honest![]() |
|
dc.contributor.author | Mzizi, Yonwaba![]() |
|
dc.contributor.author | Chalwe, Joseph![]() |
|
dc.contributor.author | Diphofa, Jeaneth![]() |
|
dc.contributor.author | Mokobodi, Dinah![]() |
|
dc.contributor.author | Gxekwa, Nobuhle![]() |
|
dc.contributor.author | Zongo, Lusanda![]() |
|
dc.contributor.author | Maphosa, Tinashe![]() |
|
dc.contributor.author | Vorster, Mariza![]() |
|
dc.contributor.author | Bassa, Sheynaz![]() |
|
dc.contributor.author | Venkatesan, Amouda![]() |
|
dc.contributor.author | Khanyile, Richard![]() |
|
dc.contributor.author | Munga, Yunus![]() |
|
dc.contributor.author | Ebenhan, Thomas![]() |
|
dc.contributor.author | Zeevaart, Jan Rijn![]() |
|
dc.contributor.author | Sathekge, Mike Machaba![]() |
|
dc.date.accessioned | 2024-08-07T12:19:24Z | |
dc.date.available | 2024-08-07T12:19:24Z | |
dc.date.issued | 2023-01-09 | |
dc.description | DATA AVAILABILITY STATEMENT : Data supporting reported results can be requested by email from both corresponding authors. | en_US |
dc.description.abstract | Patients with cancer are presumed to be vulnerable to an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe clinical outcomes due to the immunocompromised state mediated by their underlying malignancies and therapy. The aim of this study was to estimate the SARS-CoV-2 seroprevalence, following second to fourth waves in solid tumour patients attending the Steve Biko Academic Hospital (SBAH) for diagnosis and treatment of cancer. We used the single-prick COVID-19 IgG/IgM Rapid Test Cassettes to detect SARS-CoV-2 IgG/IgM antibodies in 760 patients with solid tumours who were asymptomatic and who had never tested positive for coronavirus disease 2019 (COVID-19). Out of the 760 patients, 277 were male (36.4%), 483 were female (63.6%), and the mean age was 55 years (range 18–92). The estimated total seroprevalence was 33.2%. The seroprevalence status of the COVID-19 IgG/IgM antibodies rose significantly from the second wave (11.3%) to the third (67.38%) and then the fourth (69.81%) waves with roughly similar counts. A significant number of the seropositive patients were asymptomatic to COVID-19 (96%). There was a higher rate of seropositivity in cancer patients with hypertension (p < 0.05). Patients with breast, gynaecologic, and prostate cancers exhibited increased SARS-CoV-2 seropositivity. Although oncology patients may be susceptible to SARS-CoV-2 infection, our data indicate that these patients remained asymptomatic throughout various waves with an overall COVID-19 IgG/IgM antibody seropositivity of 33.16%, suggesting no risk of severe or fatal cases of COVID-19. | en_US |
dc.description.department | Nuclear Medicine | en_US |
dc.description.librarian | am2024 | en_US |
dc.description.sdg | SDG-03:Good heatlh and well-being | en_US |
dc.description.sponsorship | The APC was self-funded by NuMeRI. | en_US |
dc.description.uri | https://www.mdpi.com/journal/jcm | en_US |
dc.description.uri | se | en_US |
dc.identifier.citation | Kgatle, M.; Das, R.; Lawal, I.; Boshomane, T.; Mokoala, K.; Gaspar, C.; Mbokazi, L.; Nkambule, N.; Gow, V.; Ndlovu, H.; et al. The SARS-COV-2 Seroprevalence among Oncology Patients. Journal of Clinical Medicine 2023, 12, 529. https://DOI.org/10.3390/jcm12020529. | en_US |
dc.identifier.issn | 2077-0383 (online) | |
dc.identifier.other | 10.3390/jcm12020529 | |
dc.identifier.uri | http://hdl.handle.net/2263/97498 | |
dc.language.iso | en | en_US |
dc.publisher | MDPI | en_US |
dc.rights | © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. | en_US |
dc.subject | IgG/IgM Antibodies | en_US |
dc.subject | Cancer | en_US |
dc.subject | COVID-19 pandemic | en_US |
dc.subject | Coronavirus disease 2019 (COVID-19) | en_US |
dc.subject | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | en_US |
dc.subject | South Africa (SA) | en_US |
dc.subject | SARS-CoV-2 seroprevalence | en_US |
dc.subject | Solid tumour patients | en_US |
dc.subject | Steve Biko Academic Hospital complex (SBAH) | en_US |
dc.subject | SDG-03: Good health and well-being | en_US |
dc.title | The SARS-COV-2 seroprevalence among oncology patients | en_US |
dc.type | Article | en_US |